These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 22386743

  • 21. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
    Patzer JA, Dzierzanowska D, Turner PJ.
    J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
    [Abstract] [Full Text] [Related]

  • 22. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW, Xu YC, Chen MJ, Hu YJ, Ni YX, Sun JY, Yu YS, Kong HS, He L, Wu WY, Ye HF, Yang YM, Zhu LN, Guo SH, Ji P, Zhu ZH, Ren JK, Zhang LX, Sun ZY, Zhu XH, Tong MQ, Zhao WS, Mei YN, Liu Y, Zhang ZJ, Duan Q, Li D, Liu PP, Wang J, Han LX, Wang H, Xie XL.
    Zhonghua Yi Xue Za Zhi; 2007 Oct 23; 87(39):2753-8. PubMed ID: 18167265
    [Abstract] [Full Text] [Related]

  • 23. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A.
    J Antimicrob Chemother; 2011 Sep 23; 66(9):2022-7. PubMed ID: 21653605
    [Abstract] [Full Text] [Related]

  • 24. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008.
    Wang H, Chen M, Ni Y, Liu Y, Sun H, Yu Y, Yu X, Mei Y, Liu M, Sun Z, Chu Y, Hu Z, Huang X.
    Int J Antimicrob Agents; 2010 Mar 23; 35(3):227-34. PubMed ID: 20047820
    [Abstract] [Full Text] [Related]

  • 25. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS, Frei CR.
    J Antimicrob Chemother; 2005 Nov 23; 56(5):893-8. PubMed ID: 16162664
    [Abstract] [Full Text] [Related]

  • 26. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P, Hasçelik G, Unal S.
    Mikrobiyol Bul; 2006 Jul 23; 40(3):147-54. PubMed ID: 17001842
    [Abstract] [Full Text] [Related]

  • 27. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
    Lee YL, Chen YS, Toh HS, Huang CC, Liu YM, Ho CM, Lu PL, Ko WC, Chen YH, Wang JH, Tang HJ, Yu KW, Liu YC, Chuang YC, Liu CE, Hsueh PR.
    Int J Antimicrob Agents; 2012 Jun 23; 40 Suppl():S29-36. PubMed ID: 22749056
    [Abstract] [Full Text] [Related]

  • 28. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP.
    Braz J Infect Dis; 2011 Jun 23; 15(5):413-9. PubMed ID: 22230846
    [Abstract] [Full Text] [Related]

  • 29. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS, Jones RN, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul 23; 52(3):203-8. PubMed ID: 16105565
    [Abstract] [Full Text] [Related]

  • 30. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
    Shanthi M, Sekar U.
    J Assoc Physicians India; 2009 Sep 23; 57():636, 638-40, 645. PubMed ID: 20214000
    [Abstract] [Full Text] [Related]

  • 31. Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
    Rahal JJ.
    Clin Infect Dis; 2009 Aug 15; 49 Suppl 1():S4-S10. PubMed ID: 19619021
    [Abstract] [Full Text] [Related]

  • 32. Comparative activity of carbapenem testing: the COMPACT study.
    Nordmann P, Picazo JJ, Mutters R, Korten V, Quintana A, Laeuffer JM, Seak JC, Flamm RK, Morrissey I, COMPACT study group.
    J Antimicrob Chemother; 2011 May 15; 66(5):1070-8. PubMed ID: 21393160
    [Abstract] [Full Text] [Related]

  • 33. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
    Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF.
    Antimicrob Agents Chemother; 2008 Dec 15; 52(12):4388-99. PubMed ID: 18779357
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
    Mendes C, Hsiung A, Kiffer C, Oplustil C, Sinto S, Mimica I, Zoccoli C, Mystic Study Group.
    Braz J Infect Dis; 2000 Oct 15; 4(5):236-44. PubMed ID: 11063555
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Comparative activity of carbapenem testing (the COMPACT study) in Turkey.
    Leblebicioglu H, Cakir N, Celen M, Kurt H, Baris H, Laeuffer J, Turkish COMPACT Study Group.
    BMC Infect Dis; 2012 Feb 16; 12():42. PubMed ID: 22340940
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.